The clinical significance of Lunx mRNA detection in plasma and peripheral mononuclear cells in patients with lung cancer

Abstract

Abstract: Objective　To investigate the clinical auxiliary diagnosis significance of lung-specific X gene （Lunx） mRNA detection in plasma and peripheral mononuclear cells in patients with lung cancer. Methods　Lunx mRNA in plasma and peripheral mononuclear cells was detected by fluorescence quantitation polymerase chain reaction （PCR） in patients with lung cancer，benign lung disease，extrapulmonary tumor and healthy subjects. Results　The positive rate of Lunx mRNA from plasma in lung cancer group was significantly higher than those in benign lung disease group （χ²=113.10，P＜0.01）， extrapulmonary tumor group （χ²=125.34，P＜0.01） and healthy subjects （χ²=100.33，P＜0.01）. The positive rate of Lunx mRNA in plasma in patients with Ⅲ-Ⅳ stages of lung cancer was significantly higher than that in patients with Ⅰ-Ⅱ stages of lung cancer （χ²=7.07，P＜0.05）. The positive rate of Lunx mRNA in peripheral mononuclear cells in lung cancer group was significantly higher than those in benign lung disease group （χ²=32.79，P＜0.01），extrapulmonary tumor group （χ²=44.44，P＜0.01） and healthy subjects （χ²=44.44，P＜0.01）. The positive rate of Lunx mRNA in peripheral mononuclear cells in patients with Ⅲ-Ⅳ stages of lung cancer was significantly higher than that in patients with Ⅰ-Ⅱ stages of lung cancer （χ²=24.52，P＜0.01）. For the auxiliary diagnosis of lung cancer, the sensitivity of Lunx mRNA detection in plasma was higher than that in mononuclear cells （χ²=36.46，P＜0.01）. The negative predictive value of the Lunx mRNA detection in plasma was higher than that in mononuclear cells （χ²=16.37，P＜0.01）. Conclusions　The detection of Lunx mRNA in plasma and peripheral mononuclear cells can be used for the auxiliary diagnosis of lung cancer. The sensitivity in plasma is higher than that in mononuclear cells.

null

Key words: Lung-specific X gene, Circulating RNA, Circulating tumor cell, Polymerase chain reaction, Lung cancer

ZHAO Wenjie;ZHOU Hongxing;WANG Sujian;WU Jiankang;WANG Jiaping;ZHANG Ping. The clinical significance of Lunx mRNA detection in plasma and peripheral mononuclear cells in patients with lung cancer[J]. , 2012, 27(8): 631-634.

References

[1]Mountain CF. Revisions in the international system for staging lung cancer[J]. Chest，1997，111（6）：1710-1717.
[2]刘桂丽，秦立萍. 肺癌X线检查误诊173例原因分析[J]. 临床误诊误治，2010，23（5）：478-479.
[3]周晴接，杨建民. 循环肿瘤细胞研究进展[J]. 世界华人消化杂志，2010，18（11）：1081-1087.
[4]Zhou H，Xu W，Qian H，et al. Circulating RNA as a novel tumor marker：an in vitro study of the origins and characteristics of extracellular RNA[J]. Cancer Lett，2008，259（1）：50-60.
[5] Xu W，Zhou H，Qian H，et al. Combination of circulating CXCR4 and Bmi-1 mRNA in plasma：a potential novel tumor marker for gastric cancer[J]. Mol Med Report，2009，2（5）：765-771.
[6]Iwao K，Watanabe T，Fujiwara Y，et al. Isolation of a novel human lung-specific gene，LUNX，a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer[J]. Int J Cancer，2001，91（4）：433-437.
[7] Mitas M，Hoover L，Silvestri G，et al. Lunx is a superior molecular marker for detection of non-small lung cell cancer in peripheral blood[J]. J Mol Diagn，2003，5（4）：237-242.
[8]谢　风，李　辉，孙晓盈. RT-PCR法检测非小细胞肺癌患者外周血Lunx mRNA的表达及临床意义[J]. 中国实验诊断学，2009，13（7）：905-907.
[9]庄　翔，刘伦旭，朱　文，等. 肺癌患者外周血中Lunx mRNA的检测及其临床意义[J]. 中国胸心血管外科临床杂志，2007，14（3）：184-187.
[10]万锦平，黄建安，刘　皓，等. 血清SCC-Ag、CYFRA21-1、NSE、CEA联合检测对肺癌的诊断价值[J]. 临床肺科杂志，2007，12（2）：111-112.
[11]高　华，张炳昌，范卫华，等. NSE、CYFRA21-1及CEA检测在肺癌诊断中的价值[J]. 山东医药，2010，50（27）：11-12.
[12]EI-Hefnawy T，Raja S，Kelly L，et al. Characterization of amplifiable，circulating RNA in plasma and its potential as a tool for cancer diagnostics[J]. Clin Chem，2004，50（3）：564-573.
[13] Swarup V，Rajeswari MR. Circulating （cell-free） nucleic acids-a promising，non-invasive tool for early detection of several human diseases[J]. FEBS Lett，2007，581（5）：795-799.
[14]李　辉，刘铁梅，孙景春，等. Lunx mRNA的表达与非小细胞肺癌外周血微转移的相关性研究[J]. 中国实验诊断学，2009，13（4）：487-489.

[1]	MA Xiaolu, GUO Lin, LU Renquan. Clinical value and application prospect of circulating biomarkers in hepatocellular carcinoma patients [J]. Laboratory Medicine, 2025, 40(4): 309-316.
[2]	HUANG Ting, XU Yan, SHI Qingxing, PENG Ying. Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients [J]. Laboratory Medicine, 2025, 40(12): 1159-1164.
[3]	XU Ben, FENG Zhangliang, SONG Xiaojun, JIN Dazhi, CHEN Yu. Research progress in molecular diagnostic techniques for respiratory tract infections [J]. Laboratory Medicine, 2025, 40(10): 1019-1024.
[4]	LU Xiuming, CHAI Baoying, CAO Yingqi, LIU Xin, YANG Lin. Roles of serum CA125，TRAP1 and HO-1 in efficacy evaluation of targeted therapy combined with chemotherapy for patients with advanced non-small cell lung cancer [J]. Laboratory Medicine, 2025, 40(10): 972-977.
[5]	REN Jixuan, HU Zhaohui, CHEN Jiachang, WANG Weishi, LIU Xiangdong, LIU Xinyuan, LI Ying. Simultaneous identification of 6 diarrhea pathogens based on probe melting curve analysis and multiple PCR [J]. Laboratory Medicine, 2024, 39(8): 793-799.
[6]	WANG Yafei, ZHANG Zhenjun, SONG Changliang, YANG Qiong. Roles of Notch1 mRNA and Dickkopf-1 in assessing the therapeutic responsiveness of pembrolizumab in non-small cell lung cancer patients [J]. Laboratory Medicine, 2024, 39(7): 627-633.
[7]	XU Chunhui, ZHOU Xinyue, YI Huiming, ZHANG Lining, CHEN Shulian, ZHU Guoqing, FENG Sizhou. Diagnostic roles of mNGS and Mucorales PCR in pulmonary mucormycosis in patients with blood diseases [J]. Laboratory Medicine, 2024, 39(12): 1145-1149.
[8]	LIU Fadi, LE Ping, WU Yinglong, LIU Huihua, YI Ting, FU Jingjing, KE Jiangwei. Sequencing analysis of hearing-impaired children with negative hearing loss gene screening results and carrying only a single heterozygous variant in GJB2 or SLC26A4 [J]. Laboratory Medicine, 2024, 39(12): 1202-1207.
[9]	CUI Xiaoyang, LIU Guodong, GUO Huijuan, LIAO Zhihong, LIU Yunhong, ZHANG Weifen, CHEN Zirao, WEI Xiaozhu. Roles of serum exosomal CEA，CA15-3 and CA125 in the differential diagnosis of non-small cell lung cancer and benign lung diseases [J]. Laboratory Medicine, 2024, 39(11): 1035-1041.
[10]	LEI Ming, ZHAI Li, WEI Ying, LIN Yichen, GUO Mengyue. Application of nomogram model based on clinical characteristics and serum tumor markers in differential diagnosis of benign and malignant lung lesions [J]. Laboratory Medicine, 2024, 39(10): 956-962.
[11]	ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18.
[12]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[13]	SHI Yingying, PAN Fen, SUN Yan, WANG Chun, JIANG Jie, YU Fangyuan, ZHANG Tiandong, QIN Huihong, ZHANG Hong. Nested multiple polymerase chain reaction in rapid diagnosis of meningitis/encephalitis in children [J]. Laboratory Medicine, 2023, 38(8): 766-770.
[14]	CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639.
[15]	DU Jinghui, HE Xin, LIU Jing, LIU Ruiyan, BAO Zhijun, WANG Jun, ZHAO Yan, LEI Yaorong, LIU Min, LIU Xu. Evaluation of 7 oscillating mixing methods for SARS-CoV-2 nucleic acid determination [J]. Laboratory Medicine, 2023, 38(7): 680-685.